Zobrazeno 1 - 10
of 15
pro vyhledávání: '"329"'
Autor:
Yasushi Miyazaki, Yoshihiro Hatta, Toru Sakura, Noriyoshi Iriyama, Hiroshi Handa, Masatomo Takahashi, Hisashi Sakamaki, Tomohiko Taki, Norio Asou, Shunichiro Yamaguchi, Tomoya Maeda, Shinya Satou, Shuichi Miyawaki, Sumihisa Honda, Shigeki Ohtake, Tomoki Naoe, Masafumi Taniwaki
Publikováno v:
Blood. 122:2608-2608
Background Immunophenotyping is a standard diagnostic procedure in leukemia, but unlike cytogenetic classifications, which are reliable indicators for prognostic interpretation, immunophenotyping has, thus far, yielded inconsistent results. Recently,
Autor:
Maanasa Gowda, Franco Locatelli, Tommaso Stefanelli, Norbert Hollaender, Shahrukh K. Hashmi, Robert Zeiser, Mary E.D. Flowers, Fitzroy Dawkins, Ronjon Chakraverty, Stephanie J. Lee, Nicola Polverelli, Takanori Teshima, Ron Ram
Publikováno v:
Blood. 136:22-24
BACKGROUND Standard first-line treatment of cGVHD includes systemic corticosteroids; however, about 50% of patients (pts) are steroid refractory or dependent (SR/D) and require additional treatment. The best second-line therapy option has not yet bee
Autor:
Mario Uhr, Francesco Forconi, Emanuele Zucca, Georg Stussi, Andrea Rinaldi, Francesco Bertoni, Michael Mian, Franco Cavalli, Ivo Kwee, Roberto Marasca, Gianluca Gaidano, Afua Adjeiwaa Mensah, Davide Rossi, Marco Ladetto
Publikováno v:
Blood. 120:3906-3906
Abstract 3906 The clinical course of CLL patients ranges from an indolent and chronic disease to a rapidly progressing leukemia or lymphoma necessitating aggressive treatment. Very recent data have shown that genomic complexity evaluated by conventio
Autor:
Franco Locatelli, Tommaso Stefanelli, Valkal Bhatt, Shashikant Apte, Nada Hamad, Stephanie J. Lee, Francesca Bonifazi, Takanori Teshima, Jackie Han, Kentaro Fukushima, Maanasa Gowda, Ivan S. Moiseev, Juan Carlos Vallejo Llamas, Joseph Pidala, Francis Ayuk, Robert Zeiser, Tsila Zuckerman, Mike Zuurman
Publikováno v:
Blood. 138:3909-3909
BACKGROUND Approximately 50% of patients (pts) who receive initial cGVHD therapy are steroid refractory or dependent (SR/D); standard second-line therapy has yet to be established. Quality of life (QOL) in these pts is poor and worsens with disease s
Autor:
Yanmin Zhao, Lizhen Liu, Yi Chen, Ying Lu, Jian Yu, Kang Yu, He Huang, Xiaoyu Lai, Jimin Shi, Huarui Fu, Fei Gao, Baodong Ye, Lieguang Chen, Jianping Lan, Xiaolu Song, Yi Luo
Publikováno v:
Blood. 138:1825-1825
Objective Hematopoietic stem cell transplantation (HSCT) is one of the most efficient treatments for hematologic malignancies. However, relapse remains the main cause of transplant failure. In myeloid neoplasia, the long-term survival for patients wh
Autor:
Shanta Chawla, Manuel Modiano, Jayaram S. Bharadwaj, Jawad Francis, Hlalah Osama, Lee S. Schwartzberg, Nishan Tchekmedyian, Francois Lebel, Gajanan Bhat
Publikováno v:
Blood. 136:34-35
Background: Eflapegrastim (Rolontis®, Efla) is a long-acting granulocyte-colony stimulating factor (G-CSF), consisting of a recombinant human G-CSF analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. Efla is not a b
Autor:
Muneer H. Abidi, Andy I. Chen, Tamas Masszi, Auayporn Nadamanee, Veronika Bachanova, Naomi N. H. Hunder, Patrick J. Stiff, Simonetta Viviani, Anna Sureda, Angelo Michele Carella, Dirk Huebner, Jan Walewski, Emily K. Larsen, Jerzy Holowiecki, Craig H. Moskowitz, Dzhelil Osmanov, John W. Sweetenham, Edward Agura
Publikováno v:
Blood. 126:3172-3172
Introduction The AETHERA trial is a phase 3, randomized, placebo-controlled trial (ClinicalTrials.gov #NCT01100502), which evaluated whether post-ASCT consolidation treatment with brentuximab vedotin (BV) could prevent disease progression in Hodgkin
Autor:
Xavier Thomas, Nicolini Franck-Emmanuel, Mohamed El Hamri, Fiorenza Barraco, Véronique Lhéritier, Maël Heiblig, Sophie Ducastelle-Lepretre, Hélène Labussière, Eric Wattel, Mauricette Michallet
Publikováno v:
Blood. 124:3679-3679
Obesity is associated with an increased risk of mortality from cardiovascular causes and from malignancies while meta-analyses have evidenced a significant association between an elevated body mass index (BMI) and the risk to develop certain hematolo
Autor:
Kimberly B. Dahlman, Megan L. Hames, Mahsa S. Talbott, Judy P. Tsai, Wade T. Iams, Nishitha Reddy, Kristy L. Richards
Publikováno v:
Blood. 124:4438-4438
Background: The use of lenalidomide is expanding to include patients with refractory or relapsed diffuse large B cell lymphoma (DLBCL). Lenalidomide is less toxic than thalidomide, but it leads to hypothyroidism in approximately 5-10% of patients tha
Autor:
Pieter Sonneveld, Chrissy H. Y. Van Beurden-Tan, Philippe Moreau, Laura Rosiñol, Walter M Gregory, Michel van Agthoven
Publikováno v:
Blood. 124:2122-2122
INTRODUCTION Multiple Myeloma (MM) is an incurable disease and its treatment is characterized by treatment sequences (treatment lines). We questioned whether a health economic (HE) model could be developed that analyses treatment sequences (TS) rathe